Fast-Track Exports: India Launches Prior Intimation System for Clinical Drug Trials

In a major move to bolster India’s position as a global pharmaceutical hub, the Central Drugs Standard Control Organization (CDSCO) has officially transitioned to a “Prior Intimation” model for specific drug export trials. Starting April 21, 2026, eligible pharmaceutical companies can bypass traditional approval wait times by notifying the regulator through the digital Sugam portal.

Cutting the Red Tape for Generic Exports

The new rule, filed under Form CT-05, specifically targets the essential research needed to register Indian generic medicines in high-value international markets.

The Shift: Instead of waiting weeks for a formal “permission to proceed,” companies now provide a “prior intimation.” Once submitted correctly on the portal, the notification serves as the regulatory green light.
The Portal: All filings must be processed via the Sugam online system, ensuring a transparent, paperless, and time-stamped digital trail.

Strict Eligibility Criteria

To maintain safety and ethical standards while increasing speed, the CDSCO has limited this fast-track system to “low-risk” scenarios:

Category	Requirement for Fast-Track
Study Type	Bioavailability (BA) and Bioequivalence (BE) studies.
Participants	Must involve healthy adult volunteers.
Drug Format	Oral dosage forms only.
Excluded Drugs	Cytotoxic, hormonal, narcotic, psychotropic, or highly variable drugs.
Global Standing	Must be already approved in India or a major market (USA, EU, UK, Japan, etc.).

The Ethics Committee as Gatekeeper

While the CDSCO is simplifying its own role, it has placed more responsibility on local Ethics Committees (EC). No study can begin without an EC approval letter. To ensure oversight, these committees must be formally registered with the Central Licensing Authority.

What This Means for the Industry

This regulatory update is expected to significantly reduce “time-to-market” for Indian drug exporters. By eliminating administrative delays for routine bioequivalence studies, the government aims to reduce the cost of research and development, allowing Indian firms to compete more aggressively in the global pharmaceutical landscape.